AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02634203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
Study NCT01230554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily disposable cosmetic tint lens
Description: Bausch \& Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
Study NCT04554238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo spring
Description: Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
Study NCT04554238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
Study NCT01033435 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01581944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 Doses Goserelin
Description: 3.6mg administered monthly for 2 months prior to myomectomy
Study NCT01581944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 Doses Goserelin
Description: 3.6mg administered monthly for 3 months prior to myomectomy
Study NCT00809523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Ion Generator
Description: Equivalent exposure to inactivated Negative Ion Generator
Study NCT00809523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light-emitting Photodiode light treatment device
Description: Light-emitting Photodiode light treatment device, used for 30 min before 8 am
Study NCT04039854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane, Sevoflurane or Desflurane
Description: The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU.
Study NCT04039854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
Study NCT00369785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil hydrochloride
Description: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
Study NCT00369785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
Study NCT03202784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353
Description: BCX7353
Study NCT03628937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Decaffeinated Green Tea Polyphenol
Description: Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
Study NCT03628937 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
Study NCT02414568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 120 mg/m2 (IV) Day 1
Study NCT02414568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 40 mg/m² PO
Study NCT02414568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6 mg/m² IV
Study NCT02414568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 40 mg/m² IV
Study NCT04408014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serological test
Description: IgM and IgG for SARS-CoV-2
Study NCT04408014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal Swab
Description: PCR for SARS-CoV-2
Study NCT04408014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oropharyngeal Swab
Description: PCR for SARS-CoV-2
Study NCT04652713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-rich breakfast
Description: High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)
Study NCT04652713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich breakfast
Description: Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)
Study NCT04652713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No breakfast
Description: 1 glas of water (150 ml)
Study NCT03244410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: complete blood picture
Description: complete blood picture
Study NCT02900183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference (RNAi)-based, liver-targeted therapeutic
Study NCT05362383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model
Description: Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
Study NCT04611620 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Dysfunction
Description: To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
Study NCT03841695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMTC finger-hand robot (Mirror Hand)
Description: The robotic hand will apply on the patient's affected hand and the sensor glove will apply on the patient's un-affected hand, the patient can manipulate their affected hand by their un-affected hand and do the task oriented bimanual training.
Study NCT03841695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional OT
Description: The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
Study NCT03841695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional OT
Description: The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
Study NCT00870766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal contrast-enhanced CT scanning
Description: Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
Study NCT03641495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PE+ET
Description: To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
Study NCT03641495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ET
Description: To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
Study NCT00300768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg moxidectin
Description: Single-dose, tablet encapsulated for blinding
Study NCT00300768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin 150 mcg/kg
Description: Single-dose, tablets encapsulated for blinding
Study NCT00300768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg moxidectin
Description: Single dose, tablets encapsulated for blinding
Study NCT00300768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin
Description: single dose, tablets encapsulated for blinding
Study NCT00797836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantiferon Gold
Description: Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/\*epidemiology/\*statistics \& numerical data Occupational Exposure/\*statistics \& numerical data~Tuberculosis/\*diagnosis/\*epidemiology/prevention \& control Immunologic Tests/methods/\*standards Disease Transmission, Horizontal/\*statistics \& numerical data Patient Isolation~Tuberculin Test/standards/\*methods Immunoassay/methods/\*standards T-Lymphocytes/immunology Interferon Type II/\*blood/\*analysis~\*Reagent Kits, Diagnostic~Mass Screening/\*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/\*methods
Study NCT03447951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-Toluenesulfonamide
Description: A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
Study NCT03659851 — intervention group
Intervention type: DRUG
Intervention: Levosimendan 2.5 MG/ML Injectable Solution
Description: LVAD implantation
Study NCT01600976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
Study NCT01849497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab Pre-filled Syringe
Description: Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
Study NCT01849497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab AI/pen
Description: Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
Study NCT02843763 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (28 ml)
Study NCT02560363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 immediate release (IR) oral suspension
Description: 120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
Study NCT02560363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [fast]
Description: 120 mg (2 x 60mg capsules) single dose
Study NCT02560363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [intermediate]
Description: 120 mg (2 x 60mg capsules) single dose
Study NCT02560363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 extended release (ER) capsules [slow]
Description: 120 mg (2 x 60mg capsules) single dose
Study NCT02897232 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
Study NCT03948633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted knowledge translation intervention
Description: The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
Study NCT01549626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Defatted flaxseed flour
Description: 30g defatted flaxseed flour per day for breakfast
Study NCT01549626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Golden flaxseed flour
Description: 30 grams of golden flaxseed flour per day for breakfast
Study NCT01549626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole brown flaxseed flour
Description: 30 grams of whole brown flaxseed flour per day for breakfast
Study NCT00354081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)
Description: folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
Study NCT00354081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid, vitamin B12 (cyanocobalamin)
Description: folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
Study NCT00354081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin B6 (pyridoxine)
Description: vitamin B6 40 mg, in a capsule, taken orally once a day
Study NCT00354081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, in a capsule, taken orally once a day
Study NCT02884154 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echotip ProCoreⓇ HD Ultrasound Biopsy Needle
Study NCT00302510 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: immunoadsorption
Description: immunoadsorption
Study NCT02955420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC 007
Study NCT02955420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 0.9 %
Study NCT00590044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine+ glulisine
Description: Daily insulin glargine + glulisine before meals
Study NCT00590044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH + Regular insulin
Description: Split-mixed NPH + Regular insulin twice daily
Study NCT01329887 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketanserin
Description: ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
Study NCT03521830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 480mg IV every 4 weeks
Study NCT03521830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg IV every 4 weeks
Study NCT03521830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg IV every 4 weeks for 4 doses
Study NCT03521830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: 480 mg IV q4wks
Study NCT01937572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visionaire system (Knee MRI)
Study NCT01937572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Knee MRI
Study NCT02437617 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Tissue
Description: Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
Study NCT02901574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal or Cathodal tDCS
Description: 2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
Study NCT02901574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
Study NCT02901574 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized naming therapy
Description: Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
Study NCT02901574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized naming therapy
Description: Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
Study NCT03581279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T2Lyme Panel testing
Description: The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.
Study NCT03160443 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders
Description: All patients assessed in the day-hospital will performed the same evaluation :~* Blood sampling~* Calorimetry~* Osteodensitometry~* Psychiatric assessment~* Endocrinologic assessment~* Dietetic assessment~* Neuropsychological assessment~* Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)
Study NCT02844621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20mg orally once daily
Study NCT01475929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplement
Description: A single strain probiotic supplement given at two doses
Study NCT01475929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: A single strain probiotic supplement given at two doses
Study NCT01514136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ostomy appliance: convex 1-piece drainable
Description: 8 variations of an ostomy devices are tested
Study NCT04236895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Glargine Injection
Description: All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
Study NCT04236895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Glargine Injection
Description: All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.